Marking the beginning of World Antimicrobial Awareness Week, Anna Zorzet and Scott Howard make the case that often the most important treatment for people with cancer are the drugs that cure their infections.
The discovery of antimicrobials is one of the greatest advances of our time. Being able to treat a multitude of different infections has saved countless lives. This is certainly true for people living with cancer, who rely on antimicrobials for the prevention and treatment of infections. Antimicrobials are also crucial for safe cancer surgery. However, global action to address drug resistant infections has not kept pace with the number or organisms that have developed resistance. Watching a person with curable cancer succumb to infection while on the road to cure is truly heartbreaking.
Case of aspergilliosis in acute myeloid leukemia
To highlight the impact of effective antimicrobials, consider acute myeloid leukemia (AML). Standard care for people with acute myeloid leukemia includes four or five cycles of intensive chemotherapy that severely suppresses patients’ immune systems and increases their likelihood of developing bacterial and fungal infections.
For example, approximately 10% of people with acute myeloid leukemia develop the fungal infection invasive aspergillosis due to exposure to spores in their environment. Aspergillosis infections in the 1980s had an overwhelmingly negative impact on patient survival: half of people with acute myeloid leukemia complicated by aspergillosis died from infection. In addition to increasing rates of mortality, these types of infections commonly caused delays and interruption to chemotherapy treatment, which increased the likelihood of relapse, so drug-resistant aspergillus had a double impact on survival.
From 1991 to 2001, cure rates for acute myeloid leukemia did not improve. But then since 2001, survival for children with acute myeloid leukemia has increased by a whopping 14%. The surprise was that this increase came despite using the same chemotherapy as before. The difference resulted from controlling aspergillus fungus infection, which had been resistant to the commonly used amphotericin but was sensitive to the newly approved anti-fungal drug voriconazole.
In the 1990s, aspergillus was resistant to the existing treatments, which led to prolonged infections, delayed chemotherapy, and increased relapse. The new antifungal drugs had a game-changing impact on outcomes for people receiving cancer therapy.
Antimicrobial resistance and lack of access to cancer care and antibiotics: a triple burden for low- and middle-income countries
Unfortunately, many patients in low-and middle-income countries have not benefited from these remarkable improvements and their related increased survival. Despite their inclusion on the WHO’s Model List of Essential Medicines, most of these life-saving drugs are either not licensed or inaccessible due to prohibitive costs and inadequate supply chains.
Thus, people with cancer in low-and middle-income countries carry the triple burden of lacking access to cancer medicines and antibiotics as well as being more exposed to resistant infections. This has had devastating consequences for cancer patient outcomes.
Dr Scott Howard, one of the UICC AMR and cancer care task force members, recently consulted on a young girl in Myanmar who developed a fungal mass in her lungs during treatment for acute leukemia that has a 90% cure rate in high-income countries. Unfortunately, voriconazole was not available to her, and her prolonged high fevers and lung damage meant that she could no longer safely receive chemotherapy. The lack of chemotherapy led to a delay in her remission, and the persistent leukemia compounded the damage from the aspergillus infection.
This inequity also leads to impossible ethical dilemmas. In India, doctors have realized that treating cancer patients exposed them to the risk of dying with an untreatable, resistant infection. What do you choose in such a situation?
Why the cancer community needs to act on antimicrobial resistance
With the number of drug-resistant infections increasing worldwide, the cancer community needs to act. Cancer physicians are concerned – as many as 95 % of polled oncologists in the UK worry about increasing drug resistance and its consequences on future cancer care.
The COVID-19 pandemic has highlighted the need for resilient health systems, reinforced the importance of managing infections that occur in people fighting cancer and resulted in an unprecedented rate of collaboration. Antimicrobials are crucial to all health systems, so we must consider how to keep them effective and sustain a high level of global collaboration to fight infections with every means at our disposal.
The creation of an AMR task force at the UICC is a welcome step but more action is needed. Cancer societies, patients and physicians need to join the debate to make the issue a political priority. Without the effectiveness of these treatments, doctors and patients risk regressing decades back to the poor survival rates of the 1970s.
- Dr Scott Howard is Secretary General of International Society of Paediatric Oncology (SIOP). He recently returned from an 18-month sabbatical to work at the World Health Organization (WHO) headquarters in Geneva to help launch the WHO Global Initiative for Childhood Cancer. Scott served as the Medical Information Officer and Chief Informaticist for the international outreach programs of St. Jude. After leaving St. Jude in 2014 he founded Resonance. He returned to academia in 2017 as a Professor at the University of Tennessee Health Science Center.
- Dr Anna Zorzet serves as a Strategic Advisor for the global network ReAct(link is external) – Action on Antibiotic Resistance, where she has worked since 2011. Previously, she occupied the position of Director of ReAct Europe for seven years. Dr Zorzet has a PhD in Medical Microbiology with a focus on antibiotic resistance from Uppsala University, Sweden. She is also a member of the UICC Task Force on Antimicrobial Resistance.
- Helle Aagaard, Deputy Director, ReAct, and Tina Chong, Vice President, Resonance, also contributed to this article.
Will you Go Blue for antimicrobial resistance?
Learn more about the WHO global color campaign for World Antimicrobial Awareness Week!
More news and opinion
- Winners ReAct Asia Pacific and Aspic Clubs photo competition 2021
- ReAct Africa Conference: Key takeaways and way forward
- World Health Assembly Special Session 2: Openings for stronger governance of the silent antibiotic resistance pandemic
- Staff interview Juan-Carlos Lopez
- ReAct highlights during World Antibiotic Awareness week 2021
- Staff interview Maria Pränting
- 5 lessons learned from Latin American Summit: Community empowerment – vital for tackling AMR
- The WHA74 Special Session on Pandemic Preparedness and Response – an opportunity to address antibiotic resistance
- ReAct announces the top 15 teams to participate in the online global design sprint Innovate4Health 2021
- City of Hyderabad joins ‘Go Blue’ campaign as part of WAAW Activities
- ReAct Europe and Uppsala University go blue to shed light on the antibiotic resistance issue
- Could the best chemotherapy be an antimicrobial drug?
- Press release: Unique collaboration between Ministry of Health, Zambia and ReAct Africa
- Mobilizing communities to act on antibiotic resistance
- ReAct activities for World Antimicrobial Awareness Week 2021
- Dr Vijay Yeldandi
- 4-day Summit: Latin America discusses the role of the community in National Action Plans on AMR
- The world needs new antibiotics – so why aren’t they developed?
- 3 ways the new WHO costing & budgeting tool supports AMR National Action Plan work
- 5 years after the UN Political Declaration on AMR – where are we now?
- Víctor Orellana
- Local production of vaccines and medicines in focus: Key points from ReAct and South Center UN HLPF side-event
- Behavior change to manage antimicrobial resistance: 8 briefs and 1 webinar-launch by Uppsala Health Summit
- ReAct and ICARS to develop policy guides and tools for low resource settings
- Tapiwa Kujinga, Director of PATAM: In Zimbabwe civil society is involved in every aspect of the response to AMR
- COVID-19: India pays a high price for indiscriminate drug use
- Lancet Global Health article release: Resetting the agenda for antibiotic resistance
- 3 key takeaways for AMR from this year’s World Health Assembly WHA74
- Antibiotic resistance – far more than a medical problem
- UN High-level Dialogue on AMR: political will and investments needed
- Resetting the agenda for antibiotic resistance through a health systems perspective
- 3 questions to newly appointed STAG-AMR members Otridah Kapona and Sujith Chandy
- Walk the talk: time is ticking for all to act on antibiotic resistance!
- Vanessa Carter: 3 years of surviving a drug-resistant infection made me want to create change
- Upcoming ReAct Webinar: Expert Conversation about new report
- ReAct report: Governments need to take more leadership to ensure global sustainable access to effective antibiotics
- 4 considerations for addressing antimicrobial resistance through pandemic preparedness
- Preventing the next pandemic: Addressing antibiotic resistance
- 4 key takeaways from the virtual ReAct Africa Conference 2020
- The threat of the unknown: is lack of global burden data slowing down work on antibiotic resistance?
- ReAct input to the WHO Executive Board Session on Antimicrobial Resistance
- Dr Gautham: informal health providers key to reducing antibiotic use in rural India